Shirley Tenesaca

Shirley Tenesaca

Auto-generated profile, based on publicly available information

Shirley Tenesaca

Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, 31008, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Annals of Translational Medicine
Verified
Journal Article
Closed access
PDF file
MVMarcos Vasquez
Marcos Vasquez
STShirley Tenesaca
Shirley Tenesaca
Pedro BerraondoPedro Berraondo
Pedro Berraondo
Antitumor therapeutic vaccines aim at priming an effector immune response able to recognize and kill tumor cells. Antitumor vaccines are composed of at least two main components: the tumor antigens and the adjuvant. Metastatic advanced melanoma has been a model disease to test novel advances in vaccine design due to the intrinsic immunogenicity of this tumor and the accessibility to melanoma lesions to monitor the immune response. In spite of a large number of clinical trials, clinical benefit remains elusive. The clinical success of monoclonal antibodies targeting immune check-points has renewed interest in novel vaccine strategies such as personalized neoantigen-based vaccines.

1 August 2019 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MVMarcos Vasquez
Marcos Vasquez
MCMarta Consuegra-Fernández
Marta Consuegra-Fernández
Fernando ArandaFernando Aranda
Fernando Aranda
AJAitor Jimenez
Aitor Jimenez
STShirley Tenesaca
Shirley Tenesaca
Pedro BerraondoPedro Berraondo
Pedro Berraondo
Multiple sclerosis (MS) is a chronic autoimmune disease with no curative treatment. The immune regulatory properties of type I IFNs have led to the approval of IFN-β for the treatment of relapsing-remitting MS. However, there is still an unmet need to improve the tolerability and efficacy of this therapy. In this work, we evaluated the sustained delivery of IFN-α1, either alone or fused to apolipoprotein A-1 by means of an adeno-associated viral (AAV) system in the mouse model of myelin oligodendrocyte glycoprotein–induced experimental autoimmune encephalomyelitis. These in vivo experiments demonstrated the prophylactic and therapeutic efficacy of the AAV–IFN-α or AAV–IFN-α fused to apolipoprotein A-1 vectors in experimental autoimmune encephalomyelitis, even at low doses devoid of hematological or neurologic toxicity. The sustained delivery of such low-dose IFN-α resulted in immunomodulatory effects, consisting of proinflammatory monocyte and T regulatory cell expansion. Moreover, encephalitogenic T lymphocytes from IFN-α–treated mice re-exposed to the myelin oligodendrocyte glycoprotein peptide in vitro showed a reduced proliferative response and cytokine (IL-17A and IFN-γ) production, in addition to upregulation of immunosuppressive molecules, such as IL-10, IDO, or PD-1. In conclusion, the results of the present work support the potential of sustained delivery of low-dose IFN-α for the treatment of MS and likely other T cell–dependent chronic autoimmune disorders.

25 June 2020 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
STShirley Tenesaca
Shirley Tenesaca
MVMarcos Vasquez
Marcos Vasquez
MFMyriam Fernandez‐Sendin
Myriam Fernandez‐Sendin
CTClaudia Augusta Di Trani
Claudia Augusta Di Trani
NANuria Ardaiz
Nuria Ardaiz
Pedro BerraondoPedro Berraondo
Pedro Berraondo

8 June 2019
Verified
Book Chapter
Closed access
Myriam Fernández SendinMyriam Fernández Sendin
Myriam Fernández Sendin
STShirley Tenesaca
Shirley Tenesaca
MVMarcos Vasquez
Marcos Vasquez
Fernando ArandaFernando Aranda
Fernando Aranda
Pedro BerraondoPedro Berraondo
Pedro Berraondo